Korea Botox Rivalry To Intensify After Meditoxin Measures

Punitive Steps To Impact Market

As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.

Lips_Injection
Medytox Found To Have Manipulated Botulinum Test Results • Source: Shutterstock

South Korea’s Ministry of Food and Drug Safety (MFDS) has decided to cancel the approval of Medytox Inc.’s botulinum toxin preparation Meditoxin (Neuronox, botulinum toxin type A complex) effective 25 June, after a finding that the company violated the Pharmaceutical Affairs Act by manipulating manufacturing and quality control documents.

The ministry has also imposed fines worth KRW175m ($144,370) relating to Innotox, Medytox’s liquid botulinum toxin product.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By 

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.